Repertoire Immune Medicines and Bristol Myers Squibb link on autoimmune disease vaccines Repertoire CEO Torben Straight Nissen stated: “This agreement is a recognition of the transformative power of Repertoire’s DECODE platform to discover and develop programmable T cell targeted immune medicines. This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease.” Bristol Myers Squibb Immunology and Cardiovascular Thematic Research Center senior vice-president and head Francisco Ramirez-Valle, MD, PhD, FAAD stated: “Our collaboration with Repertoire aims to selectively reset the immune system, reflecting a key component of our immunology research strategy, which we believe may offer long-term benefit while mitigating unintended consequences associated with broad immune suppression.” - https://lnkd.in/dACnVkVe #pharma #autoimmunedisease #vaccines #drugdevelopment
Pharmaceutical-Technology
Internet News
London , England 1,804 followers
The leading site for data driven news in the pharmaceutical industry. Part of GlobalData
About us
Pharmaceutical-technology.com is one of a network of 30+ proprietary B2B websites, with an unrivalled global audience of active decision makers, influencers, and opinion leaders across the world with a combined readership of 55 million industry professionals each year. As part of GlobalData, we have access to over 1bn data points including companies, deals, projects and forecasts and trends. Leading data informs and supports our industry leading content. With expertise spanning more than 80 markets globally and driven by 800+ award-winning journalists, researchers, and analysts, we connect you with the information that makes and breaks businesses every day. Combined with our award-winning targeting technology built into our network of websites, we offer a unique end-to-end marketing solution combining insight, creativity, and cutting-edge AI-technology. Our marketing solution allows clients to identify, target and engage with prospects using access and ownership of our 30+ B2B media websites and their large sector specific audiences. With more reach, data targeting and first-party data than any other partner, we produce world-class campaigns for our clients. For more details on our technology-driven marketing solution visit www.globaldatamarketingsolutions.com
- Website
- www.pharmaceutical-technology.com
External link for Pharmaceutical-Technology
- Industry
- Internet News
- Company size
- 501-1,000 employees
- Headquarters
- London , England
- Type
- Public Company
Locations
- Primary
John Carpenter Street
John Carpenter House
London , England EC4Y 0AN, GB
Updates
-
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding US regulators have added more Chinese biotech companies to the list of firms posing national security risks to the US. - https://lnkd.in/dBHNMzfr #biosecurebill #biotech #pharma
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding - Pharmaceutical Technology
pharmaceutical-technology.com
-
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche. - https://lnkd.in/gkuQTR7n #pharma #biopharma #medicare
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
pharmaceutical-technology.com
-
Merck’s net income for Q1 2024 increases by 69% to $4.76bn The company’s sales for Q1 2024 increased by 9% to $15.77bn. - https://lnkd.in/dAuaqe8e #pharma
Merck's net income for Q1 2024 increases by 69% to $4.76bn
pharmaceutical-technology.com
-
The privileged status of orphan medicines in Germany GlobalData Healthcare has therefore taken the opportunity to assess the current situation of orphan drugs in the German oncology market. - https://lnkd.in/g_miixFh #orphandrugs #oncology #pharma
The privileged status of orphan medicines in Germany - Pharmaceutical Technology
pharmaceutical-technology.com
-
ESCMID 2024: Using AI in infection prevention and control Artificial intelligence tools can be used for infection control through facial recognition systems designed to identify proper face mask use within hospitals. - https://lnkd.in/gGvn3FnE #infectioncontrol #ai #aiinhealthcare
ESCMID 2024: Using AI in infection prevention and control - Pharmaceutical Technology
pharmaceutical-technology.com
-
Partner Content - Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture In the first of a 5 part podcast series titled “Digital Deals in Life Sciences – What Makes Them Different?” life sciences industry M&A veteran and Sterling Technology | Virtual Data Rooms board advisor John Easton will discuss how these differ from traditional life science deals, and what both parties should look out for to increase the chances of deal success, mitigate risks, and avoid failure. - https://lnkd.in/dKSY59jw #pharma #manda #digitaldeals #healthcare #lifescience
Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture - Pharmaceutical Technology
pharmaceutical-technology.com
-
Regeneron and Mammoth Biosciences team up to develop gene editing therapies Regeneron Genetic Medicines senior vice-president and co-head Christos Kyratsous said: “After years spent developing our next-generation delivery approaches, we are eager to combine them with Mammoth’s gene editing systems to better match payload, delivery system and disease type.” Mammoth Biosciences co-founder and CEO Trevor Martin added: “Mammoth’s ultracompact CRISPR systems address the size constraints of viral delivery and complement Regeneron’s targeted AAV technologies. We look forward to working with Regeneron to enable all-in-one AAV delivery and unlock the true potential of in vivo gene editing.” - https://lnkd.in/dEVcNWN6 #pharma #geneediting #aav #genetherapy #crispr
Regeneron and Mammoth team up to develop gene editing therapies
pharmaceutical-technology.com
-
Life science SMEs “heading out of the funding winter” Speakers discuss how SMEs can attract capital after a rise in investment activity in Q1 2024 compared to the last quarter of 2023. - https://lnkd.in/dJG8fq2n #pharma #pharmafunding #lifescienceinvestment
Life science SMEs “heading out of the funding winter” - Pharmaceutical Technology
pharmaceutical-technology.com
-
Sanders takes aim at US drug prices of Novo Nordisk’s Ozempic and Wegovy A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs. - https://lnkd.in/dD-jJWcZ #wegovy #ozempic #diabetes #drugpricing #pharma
Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy - Pharmaceutical Technology
pharmaceutical-technology.com